Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Korea Disease Control and Prevention Agency. Update on COVID-19 Vaccination. Updated 2021. Available online: https://ncv.kdca.go.kr/ (accessed on 21 April 2021).
- Longchamps, C.; Ducarroz, S.; Crouzet, L.; Vignier, N.; Pourtau, L.; Allaire, C.; Colleville, A.C.; El Aarbaoui, T.; Melchior, M.; ECHO Study Group. COVID-19 Vaccine Hesitancy among Persons Living in Homeless Shelters in France. Vaccine 2021, 39, 3315–3318. [Google Scholar] [CrossRef] [PubMed]
- Schwarzinger, M.; Watson, V.; Arwidson, P.; Alla, F.; Luchini, S. COVID-19 Vaccine Hesitancy in a Representative Working-Age Population in France: A Survey Experiment Based on Vaccine Characteristics. Lancet Public Health 2021, 6, e210–e221. [Google Scholar] [CrossRef]
- Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; et al. Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet 2020, 396, 1979–1993. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
- Jung, J. Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications. J. Korean Med. Sci. 2021, 36, e59. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.H.; Wi, Y.M.; Yun, S.Y.; Ryu, J.S.; Shin, J.M.; Lee, E.H.; Seo, K.H.; Lee, S.H.; Peck, K.R. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: A Single Center Experience. J. Korean Med. Sci. 2021, 36, e107. [Google Scholar] [CrossRef] [PubMed]
- Krammer, F. SARS-CoV-2 Vaccines in Development. Nature 2020, 586, 516–527. [Google Scholar] [CrossRef] [PubMed]
- Chapin-Bardales, J.; Gee, J.; Myers, T. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA 2021, 325, 2201–2202. [Google Scholar] [CrossRef] [PubMed]
- Menni, C.; Klaser, K.; May, A.; Polidori, L.; Capdevila, J.; Louca, P.; Sudre, C.H.; Nguyen, L.H.; Drew, D.A.; Merino, J.; et al. Vaccine Side-Effects and SARS-CoV-2 Infection after Vaccination in Users of the COVID Symptom Study App in the UK: A Prospective Observational Study. Lancet Infect. Dis. 2021, 21, 939–949. [Google Scholar] [CrossRef]
- Lee, Y.W.; Lim, S.Y.; Lee, J.H.; Lim, J.S.; Kim, M.; Kwon, S.; Joo, J.; Kwak, S.H.; Kim, E.O.; Jung, J.; et al. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea. J. Korean Med. Sci. 2021, 36, e153. [Google Scholar] [CrossRef] [PubMed]
- European Medicines Agency. COVID-19 Pandemic. Updated 2021. Available online: https://www.ema.europa.eu (accessed on 18 April 2021).
- Cines, D.B.; Bussel, J.B. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N. Engl. J. Med. 2021, 384, 2254–2256. [Google Scholar] [CrossRef] [PubMed]
- Shimabukuro, T.T.; Cole, M.; Su, J.R. Reports of Anaphylaxis after Receipt of mRNA COVID-19 Vaccines in the US—14 December 2020–18 January 2021. JAMA 2021, 325, 1101–1102. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. COVID-19. Updated 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html/ (accessed on 27 May 2021).
Characteristics | BNT162b2 (n = 80) | AZD1222 (n = 1431) | p Value *B 1st vs. B 2nd/ B 1st vs. A 1st/ B 2nd vs. A 1st | |
---|---|---|---|---|
After 1st Dose | After 2nd Dose | After 1st Dose | ||
Clinical characteristics | ||||
Sex (male) | 31 (38.8) | 388 (27.1) | 0.024 | |
Age (mean ± SD) | 35.83 ± 10.99 | 35.84 ± 11.13 | 0.993 | |
Type of Occupation | 0.078 | |||
Nurses and nursing assistants | 44 (55) | 743 (51.9) | ||
Doctors | 18 (22.5) | 206 (14.4) | ||
Other medical workers | 7 (2.9) | 235 (16.4) | ||
Non-medical staff and others | 11 (4.3) | 247 (17.3) | ||
All adverse events | 42 (52.5) | 61 (76.2) | 1301 (90.9) | 0.003/<0.001/<0.001 |
Adverse events requiring medication | 6 (7.5) | 36 (45.0) | 1015 (70.9) | <0.001/<0.001/<0.001 |
Local reaction | ||||
Pain at the injection site | 41 (51.2) | 54 (67.5) | 1114 (77.8) | 0.036/<0.001/0.032 |
Symptom onset | 1 (1–1) | 1 (1-1) | 1 (1–1) | |
Duration | 2 (1–3) | 2 (1–2) | 3 (2–4) | |
Redness/swelling at the injection site | 8 (10.0) | 2 (2.5) | 352/1415 b (24.9) | 0.050/0.002/<0.001 |
Symptom onset | 1 (1–1) | 1,2 | 2 (1–3) | |
Duration | 2 (2–2.75) | 3,1 | 2 (1–3) | |
Lymphadenopathy | 0 (0.0) | 1 (1.2) | 14 (1.0) | >0.999/>0.999/0.811 |
Symptom onset | 2 | 2 (1–3.5) | ||
Duration | 2 | 1 (1–1) | ||
Systemic Events | ||||
Fever | 4 (5.0) | 16 (20.0) | 517 (36.1) | 0.004/<0.001/<0.001 |
Mean ± SD | 37.6 a | 38.1 ± 0.6 | 38.3 ± 0.6 | 0.211/0.754/>0.999 |
Symptom onset | 1 (1–1) | 1 (1–1) | 1 (1–2) | |
Duration | 1 (1–1.75) | 2 (1–2) | 1 (1–2) | |
Chills | 1 (1.2) | 19 (23.8) | 589 (41.2) | <0.001/<0.001/0.002 |
Symptom onset | 1 | 1 (1–2) | 1 (1–1) | |
Duration | 1 | 1 (1–2) | 1 (1–2) | |
Fatigue | 6 (7.5) | 24 (30.0) | 726 (50.7) | <0.001/<0.001/<0.001 |
Symptom onset | 1 (1–1.25) | 1 (1–2) | 1 (1–2) | |
Duration | 2 (1.74–2.5) | 2 (1–2) | 2 (1–2) | |
Nausea | 1 (1.2) | 5 (6.2) | 327/1411 b (23.2) | 0.210/<0.001/<0.001 |
Vomiting | 2 (2.5) | 1 (1.2) | 53/1411 b (3.8) | 0.999/0.765/0.250 |
Symptom onset | 1,1 | 1.5 (1–2) | 1 (1–2) | |
Duration | 2,3 | 1 (1–1) | 1 (1–2) | |
Headache | 6 (7.5) | 25 (31.2) | 678 (47.4) | <0.001/<0.001/0.005 |
Symptom onset | 1 (1–2.5) | 1 (1–2) | ||
Duration | 2 (1–2.25) | 2 (1–2) | ||
Myalgia | 9 (11.2) | 31 (38.8) | 866 (60.5) | <0.001/<0.001/<0.001 |
Symptom onset | 1 (1–2) | 2 (1–2) | 1 (1–1) | |
Duration | 2 (1–2) | 1 (1–2) | 1 (1–2) | |
Arthralgia | 0 (0.0) | 16 (20.0) | 381 (26.6) | <0.001/<0.001/0.190 |
Symptom onset | 1.5 (1–2) | 1 (1–2) | ||
Duration | 1 (1–2) | 1 (1–2) | ||
Allergic reactions | ||||
Urticaria | 0 (0.0) | 0 (0.0) | 42 (2.9) | NA/0.166/0.166 |
Symptom onset | 1 (1–2) | |||
Duration | 1 (1–1) |
Recipients with Adverse Event | Recipients without Adverse Event | p-Value | |
---|---|---|---|
BNT162b2 Vaccine 1st | 42 (52.5) | 38 (47.5) | |
Age | 36.33 ± 9.46 | 35.26 ± 12.57 | 0.671 |
Sex | 0.428 | ||
Male | 18 (51.8) | 13 (41.9) | |
Female | 24 (49.0) | 25 (51.0) | |
BNT162b2 Vaccine 2nd | 61 (76.2) | 19 (23.8) | |
Age | 33.57 ± 8.70 | 43.21 ± 14.20 | 0.010 |
Sex | 0.462 | ||
Male | 36 (59.0) | 13 (68.4) | |
Female | 25 (41.0) | 6 (31.6) | |
AZT1222 1st | 1301 (90.9) | 130 (9.1) | |
Age | 35.19 ± 10.76 | 42.34 ± 12.64 | <0.001 |
Sex | <0.001 | ||
Male | 331 (85.3) | 57 (14.7) | |
Female | 970 (93.0) | 73 (7.0) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wi, Y.-M.; Kim, S.-H.; Peck, K.-R. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers. Vaccines 2021, 9, 931. https://doi.org/10.3390/vaccines9080931
Wi Y-M, Kim S-H, Peck K-R. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers. Vaccines. 2021; 9(8):931. https://doi.org/10.3390/vaccines9080931
Chicago/Turabian StyleWi, Yu-Mi, Si-Ho Kim, and Kyong-Ran Peck. 2021. "Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers" Vaccines 9, no. 8: 931. https://doi.org/10.3390/vaccines9080931
APA StyleWi, Y. -M., Kim, S. -H., & Peck, K. -R. (2021). Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers. Vaccines, 9(8), 931. https://doi.org/10.3390/vaccines9080931